Cost-benefit analysis of clinical pharmacist intervention in preventing adverse drug events in the general chronic diseases outpatients.
Rajaa A Al-QudahDaoud Al-BadriyehFarah M Al-AliShoroq M AltawalbehOlivia Stephanie HendraPublished in: Journal of evaluation in clinical practice (2019)
The RCT-based cost-benefit evaluation provided evidence-based insight into the economic benefit of a clinical pharmacist-provided HMMR for preventing ADEs in the general chronic diseases outpatients. This intervention method against the TRPs among outpatients is cost beneficial and offers substantial cost savings to the health care hospital payer in Jordan.